100 years since the 1918 influenza pandemic

References

• Grist NR. Pandemic influenza 1918. Br Med J. 1979;2:1632–3. doi:10.1136/bmj.2.6205.1632. PMID:394807
   PubMedGoogle Scholar
• Cruz E, Cain J, Crossett B, Kayser V. Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin 1 through tandem mass spectrometry. Human Vaccines Immunotherapeutics 2018;14:508–517.
   PubMed Web of Science ®Google Scholar
• Chong Y, Ikematsu H. Is seasonal vaccination a contributing factor to the selection of influenza epidemic variants? Human Vaccines Immunotherapeutics 2018;14:518–522.
   PubMed Web of Science ®Google Scholar
• Orsi A, Colomba GME, Pojero F, Calamusa G, Alicino C, Trucchi C, Canepa P, Ansaldi F, Vitale F, Tramuto F. Trends of influenza B during the 2010–2016 seasons in two regions of north and south Italy: the impact of the vaccine mismatch on influenza immunisation strategy. Human Vaccines Immunotherapeutics 2018;14:523–531.
   Web of Science ®Google Scholar
• Liu L, Lu J, Li Z, Zhou J, Guo J, Li X, Liu J, Shu Y, Wang D. 220 mutationin the hemagglutinin of avian influenza A (H7N9) virus alters antigenicity during vaccine strain development. Human Vaccines Immunotherapeutics 2018;14: 532–539. doi:10.1080/21645515.2017.1419109.
   Web of Science ®Google Scholar
• Smetana J, Chlibek R, Shaw J, Splino M, Prymula R. Influenza vaccination in the elderly. Human Vaccines Immunotherapeutics 2018;14: 540–549. PMID:29461919
   PubMed Web of Science ®Google Scholar
• Tregoning JS, Russell RF, Kinnear E. Adjuvanted influenza vaccines. Human Vaccines Immunotherapeutics 2018;14: 550–564.
   PubMed Web of Science ®Google Scholar
• Hung IFN, Yuen KY. Immunogenicity, safety and tolerability of intradermal influenza vaccines. Human Vaccines Immunotherapeutics 2018;14: 565–570.
   PubMed Web of Science ®Google Scholar
• Mohn KGI, Smith I, Sjursen H, Cox R. Immune responses after live attenuated influenza vaccination. Human Vaccines Immunotherapeutics 2018;14: 571–578.
   PubMed Web of Science ®Google Scholar
• Stevanovic G, Lavadinovic L, Filipovic Vignjevic S, Holt R, Ilic K, Berlanda Scorza F, Sparrow E, Stoiljkovic V, Torelli G, Madenwald T, et al. Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults. Human Vaccines Immunotherapeutics 2018;14: 579–586.
   PubMed Web of Science ®Google Scholar
• Choi WS, Noh JY, Lee J, Choi JY, LEE JS, Kim MS, Kim HS, Bang J, Lavis N, Kim WJ. Immunogenicity and safety of a split-virion quadrivalent influenza 1 vaccine in adults 18–60 years of age in the Republic of Korea. Human Vaccines Immunotherapeutics 2018;14:587–592.
   Web of Science ®Google Scholar
• Montalban C, Book Montellano MB, Jaime Santos J, Nathalie Lavis. Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine. Human Vaccines Immunotherapeutics 2018;14:593–595.
   PubMed Web of Science ®Google Scholar
• Sesay S, Brzostek J, Meyer I, Donazzolo Y, Leroux-Roels G, Rouzier R, Astruc B, Szymanski H, Toursarkissian N, Vandermeulen C, et al. Safety, immunogenicity, and lot-to-lot consistency of a split-virion 1 quadrivalent influenza vaccine in younger and older adults: a phase 2 III randomized, double-blind clinical trial. Human Vaccines Immunotherapeutics 2018;14:596–608.
   PubMed Web of Science ®Google Scholar
• Sarsenbayeva G, Volgin Y, Kassenov M, Issagulov T, Bogdanov N, Sansyzbay A, Stukova M, Buzitskaya Z, Кulmagambetov I, Davlyatshin T, et al. Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: results of a randomized, comparative, phase II clinical 2 trial in adults. Human Vaccines Immunotherapeutics 2018;14:609–614.
   PubMed Web of Science ®Google Scholar
• Long Y, Ma L, Liu Z, Song S, Geng X, Yang F, Guo Q, Li Z, Li W, Liao G. Preparation and evaluation of a novel, live, attenuated influenza H1N1 vaccine strain produced by a modified classical reassortment method. Human Vaccines Immunotherapeutics 2018;14:615–622. PMID:29049008
   PubMed Web of Science ®Google Scholar
• Zhou S, Ren T, Gu H, Wang C, Li M, Zhao P, Li X, Zhang L, Sun Y, Yang P, et al. Early and improved protective immunity of fractional dose of influenza H7N9 split vaccine with intradermal delivery in mice and rats. Human Vaccines Immunotherapeutics 2018;14:623–629. doi:10.1080/21645515.2017.1423156.
   Web of Science ®Google Scholar
• Wang Y, Chen L, Cheng Y, Zhou S, Pang Y, Zhang J, Greene CM, Song Y, Zhang T, Zhao G. Potential impact of B lineage mismatch on trivalent influenza vaccine effectiveness during the 2015–2016 influenza season among nursery school children in Suzhou, China. Human Vaccines Immunotherapeutics 2018;14:630–636.
   Web of Science ®Google Scholar
• Castrucci MR. Factors affecting immune responses to the influenza vaccine. Human Vaccines Immunotherapeutics 2018;14:637–646.
   PubMed Web of Science ®Google Scholar
• Ward BJ, Pillet S, Charland N, Trepanier S, Couillard J, Landry N. The establishment of surrogates and correlates of protection: useful tools for the 1 licensure of effective influenza vaccines? Human Vaccines Immunotherapeutics 2018;14:647–656. doi:10.1080/21645515.2017.1413518. PMID:29252098
   PubMed Web of Science ®Google Scholar
• Trombetta CM, Gianchecchi E, Montomoli E. Influenza vaccines: evaluation of the safety profile. Human Vaccines Immunotherapeutics 2018;14: 657–670. doi:10.1080/21645515.2017.1423153. PMID:29297746
   PubMed Web of Science ®Google Scholar
• Zheng Y, Chen L, Zou J, Zheng-Gang Z, Zhu L, Wan J, Hu Q. The safety of influenza vaccine in clinically cured leprosy patients in China. Human Vaccines Immunotherapeutics 2018;14: 671–677.
   Web of Science ®Google Scholar
• Agor J, Ozaltin OY. Models for predicting the evolution of influenza to inform vaccine strain selection. Human Vaccines Immunotherapeutics 2018;14: 678–683. doi:10.1080/21645515.2017.1423152. PMID:29337643
   PubMed Web of Science ®Google Scholar
• Principi N, Camilloni B. Esposito S for the ESCMID Vaccine Study 5 Group (EVASG). Influenza immunization policies: which could be the main reasons for differences among countries? Human Vaccines Immunotherapeutics 2018;14: 684–692.
   Web of Science ®Google Scholar
• Rizzo C, Rezza G, Ricciardi W. Strategies in recommending influenza vaccination in Europe and US. Human Vaccines Immunotherapeutics 2018;14: 693–698.
   PubMed Web of Science ®Google Scholar
• Bonanni P, Boccalini S, Zanobini P, Dakka N, Lorini C, Santomauro F, Bechini A. The appropriateness of the use of influenza vaccines: recommendations from the latest 1 seasons in Italy. Human Vaccines Immunotherapeutics 2018;14: 699–705.
   Web of Science ®Google Scholar
• Isenor JE. Patient experiences with influenza immunizations administered by pharmacists. Human Vaccines Immunotherapeutics 2018;14: 706–711. doi:10.1080/21645515.2018.1423930. PMID:29303681
   PubMed Web of Science ®Google Scholar
• Mahroum N, Watad A, Rosselli R, Brigo F, Chiesa V, Siri A, Ben-Ami Shor D, Martini N, Bragazzi NL, Adawi M. An infodemiological investigation of the so-called “Fluad effect” during the 2014/2015 influenza vaccination campaign in Italy: ethical and historical implications. Human Vaccines Immunotherapeutics 2018;14: 712–718. doi:10.1080/21645515.2017.1420448. PMID:29293392
   PubMed Web of Science ®Google Scholar
• Quinn S. African American adults and seasonal influenza vaccination: changing our approach can move the needle. Human Vaccines Immunotherapeutics 2018;14: 719–723.
   PubMed Web of Science ®Google Scholar
• Restivo VCC, Bono S, Maniglia M, Marchese V, Ventura G, Casuccio A, Tramuto F, Vitale F. Influenza vaccine effectiveness among high-risk groups: a systematic literature review and 2 meta-analysis of case-control and cohort studies. Human Vaccines Immunotherapeutics 2018;14: 724–735.
   Web of Science ®Google Scholar
• Gravenstein S, Davidson HE, Han LF, Ogarek JA, Dahal R, Gozalo PL, Taljaard M, Mor V. Feasibility of a cluster-randomized influenza vaccination trial in U.S. nursing homes: lessons learned. Human Vaccines Immunotherapeutics 2018;14: 736–743.
   Google Scholar
• Heo JY, Song JY, Noh JY, Choi MJ, Yoon JG, Lee SN, Cheong HJ, Kim WJ. Effects of influenza immunization on pneumonia in the elderly. Human Vaccines Immunotherapeutics 2018;14: 744–749.
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S. Protection of children against influenza: emerging problems. Human Vaccines Immunotherapeutics 2018;14: 750–757.
   Web of Science ®Google Scholar
• Nunes MC, Madhi SA. Influenza vaccination during pregnancy for prevention of influenza confirmed illness in the infants: a systematic review and meta-analysis. Human Vaccines Immunotherapeutics 2018;14: 758–766.
   Web of Science ®Google Scholar
• Ellingson M, Chamberlain AT. Beyond the verbal: pregnant women's preferences for receiving influenza and Tdap 1 vaccine information from their obstetric care providers. Human Vaccines Immunotherapeutics 2018;14: 767–771. doi:10.1080/21645515.2018.1425114. PMID:29313417
   PubMed Web of Science ®Google Scholar
• Dini G, Toletone A, Massa E, Sticchi L, Montecucco A, Orsi A, Bragazzi NL, Durando P. Influenza vaccination in healthcare workers: a comprehensive critical appraisal of the literature. Human Vaccines Immunotherapeutics 2018;14: 772–789.
   PubMed Web of Science ®Google Scholar
• Fedson DS. Clinician-initiated research on treating the host response to pandemic influenza. Human Vaccines Immunotherapeutics 2018;14: 790–795.
   PubMed Web of Science ®Google Scholar
• Berry CM. Antibody immunoprophylaxis and immunotherapy for influenza virus infection: utilization of monoclonal or polyclonal antibodies? Human Vaccines Immunotherapeutics 2018;14: 796–799.
   PubMed Web of Science ®Google Scholar